1 The response to romazarit, a disease modifying anti-rheumatoid agent, was observed in patients with rheumatoid arthritis (RA) in a double-blind placebo controlled study. 2 Two hundred and twenty-four patients were recruited from 11 centres and treated with placebo or romazarit at a dose of 200 mg or 450 mg every 12 h for up to 24 weeks. Disease activity was measured using the Ritchie Index (RI). Plasma concentrations of romazarit were measured at each of up to eight assessments of RI. 3 The effect of romazarit was examined using analysis of variance (ANOVA) in 164 patients who contributed 61% of observations of disease activity. Observations after 12 weeks of treatment were excluded from ANOVA. 4 A population pharmacokinetic-dynamic model for the time course of disease progress and the response to placebo and romazarit was used to describe observations from all patients. 5 The population model suggested that the effect of romazarit was on the rate of progress of the disease and was describable by an Emax model. Concentration was a better predictor of response than dose. 6 Romazarit was significantly better than placebo in improving the RI in patients with RA. The placebo efficacy of romazarit treatment was similar to that associated with placebo treatment. 7 The population model provided a more complete description and explanation of the clinical pharmacology and therapeutic potential of romazarit than ANOVA.
Introduction
Romazarit is rapidly and extensively absorbed but its Romazarit has shown disease modifying activity in pharmacokinetics are non-linear in healthy volunteers animal models which mimic some aspects of human [1] and patients with rheumatoid arthritis (RA) [2] .
RA [3] . The plasma romazarit concentrations assoThe clearance of romazarit decreases with increasing ciated with efficacy in one of these models, Type II dose perhaps due to saturable renal tubular secretion collagen arthritis, were in the range of 50-100 mg 1-1 of romazarit ester glucuronide. This is the main meta-(0.16-3.2 mmol 1-l) ( Bloxham, personal communibolite appearing in the urine and it appears to undercation), a range that provided a target concentration go reversible metabolism to the parent compound in for an efficacy study in patients with RA. vivo. This non-linearity is expected to contribute to A Phase II efficacy study of romazarit has been considerable inter-individual variability in romazarit performed in patients with RA. However, further concentrations.
clinical development of this compound has been stopped. We have used this study to demonstrate how a population pharmacodynamic analysis can enhance understanding of the clinical pharmacology of a drug at an early stage of drug development. A single measure of disease activity, the Ritchie Index, was chosen to illustrate the technique. Other disease markers and further details of the results of the clinical trial are not reported in order to focus on the methodological aspects of the population analysis approach.
Analysis of variance model
Analysis of variance was performed using PROC GLM [6] . The model included effects of baseline RI, centre, treatment and centre by treatment interaction.
The observations for the ANOVA were restricted to those collected during the first 12 The concentration of active drug in the effect compartment (Ce(t)) is then determined by a single parameter, the effect compartment equilibration halftime, t/2,eq,A:
ln (2) Ce(t) = Cav (1 -e t,2, eq, A
The concentration of placebo substance in the effect compartment is modelled in a similar way but is considered to arise from a single bolus input of placebo at the start of the double-blind treatment phase rather than continuous input as for active treatment. The time course of placebo concentration in plasma is assumed to disappear with a half-time, tI/2,el,p, while the placebo substance equilibration with its effect site is determined by the placebo equilibration half-time, tl/2,eq,P. These two half-times determine the time course of placebo concentration at its effect site:
ln (2) Ce(t) =
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. (e tl/2. ,eqP ln(2) ln (2) tl/2,eq,P tI/2,el,P being proportional to the dose or from the measured plasma concentration. The measured concentrations were treated as if they were equivalent to the average steady state concentration. The timing of the romazarit concentration measurement was scattered throughout the dosing interval so we expect that on average the measured values would be a reasonable approximation of the steady state value and potentially a better approximation than the dose alone which necessarily assumes all patients have the same clearance and bioavailability.
Pharmacodynamic models A linear pharmacodynamic model was used to describe the effect of placebo (with potency jp) or active substance concentration (with potency PA) on the parameters of the disease progress curve. An Emax model [8] was also examined to describe the effect of romazarit in terms of the parameters EmaxA and EC5OA. The placebo efficacy of romazarit (EA) treatment compared with placebo treatment was included in the model as a factor multiplying the placebo treatment potency parameter (np) when the patient was treated with romazarit.
Variability models The variability in the patient population of the PKPD model parameters was described using a proportional model. The variability parameter estimates can be considered as coefficients of variation of a log-normal distribution of the parameters in the population. The residual error was predicted by an additive error model. ln (2) Computation Parameter estimation and model build---t2. elP ing were performed using NONMEM [9] Version IV level 1.1 and NMTRAN version II level 1.1 using an HP9000/730 computer. Smoothed plots were generated using LOWESS [10] with a smoothing factor of 0.2.
Model implementation
Slope model A precise solution to the slope model would require the solution of a system of differential equations. Because of computational resource limitations we chose to approximate the solution in a piecewise fashion by extrapolating from one observation to the next using the slope predicted at the time of the earlier observation. The error arising from the piecewise approximation used with the slope model is greatest when effect site concentrations are not at steady state and the interval between observations is long compared with the equilibration half-time. In an attempt to minimize this error, which is greatest for the prediction of the first post treatment observation at 2 weeks (because this would be based on the slope predicted from a pre-treatment concentration of zero), the model used a value of plasma concentration immediately after starting treatment equal to the 2 week measured value.
Effect site concentrations The concentration of active substance at its effect site was predicted using an effect compartment model driven by the average steady state plasma concentration of romazarit. Romazarit concentrations were either predicted as
Results
A total of 224 patients entered the study. Two hundred and twenty of these patients had observations suitable for use in the population PKPD analysis. Figure 1 shows the time course of the mean romazarit concentration at each visit. There was no Figure 1 The time course of mean plasma romazarit concentration ± s.e. mean in all patients. 0 400 mg day-l, (Table 1) . One hundred and sixtyfour patients (75% of total) completed at least 12 weeks of either the placebo or romazarit treatment and were eligible for ANOVA. The ANOVA revealed a significant baseline effect and there was a suggestion of a centre effect but no significant overall treatment effect (Table 2 ). There was, however, a significant difference between the change in RI observed in the placebo group and the 900 mg day-l group (Table 3) .
The 220 patients examined using the population PKPD approach contributed 1336 paired observations of RI and romazarit concentration (73 placebo patients, 75 patients on 400 mg day-l mean concentration = 13.0 ± 0.9 (s.e. mean) mg 1-1, and 72 patients on 900 mg day-mean concentration = 44.6 + 4.3 mg 1-1).
The best PKPD model was assessed using the NONMEM objective function. A difference in the objective function of 3.84 for an additional parameter in the model can be interpreted as a significant change in the fit (P = 0.05). Table 4 shows the objective function associated with some of the models that were examined. The efficacy of the placebo response associated with romazarit was not significantly different from the response following placebo treatment. The influence of romazarit was described somewhat better by an effect on the slope of the disease progress model than an offset to the baseline (difference in objective function = 4.3). Measured romazarit concentration was a better predictor than dose (difference in objective function = 20. 8 ). An Emax model was better than a linear model (difference in objective function = 26.3). The effect due to placebo was best described with a delay (difference in objective function = 20.1).
Estimates of the population parameter typical values and their variability are shown in (Figures 2 and 3) . A confidence interval for the size of the romazarit EmaxA can be estimated by constructing a log likelihood profile. This was done by fixing EmaxA to values around the final estimate and re-estimating the other parameters. A curve was drawn through the loglikelihood values using cubic spline interpolation (Figure 4) . The values of EmaxA associated with a 3.84 unit change in log-likelihood define the 95% confidence interval for EmaxA of -1.87 to -0.25 RI units/week.
Discussion
Romazarit appears to be effective as a disease modifying antirheumatic drug in patients with RA. Modification of the rheumatoid disease process has been measured using a symptomatic scale. The magnitude of the improvement in RI estimated in this study is dependent on the statistical technique used and the assumptions about how romazarit might work. The ANOVA method predicts a difference between placebo and romazarit of 4.5 units after 12 [11, 12] . The estimate of the placebo efficacy, CA, for romazarit treatment was not different from 1 which means that the placebo response from placebo and romazarit treatments was indistinguishable.
The ANOVA results were based on a subset of patients enrolled in the trial and covers a more limited period. The population approach allowed all observations to be used and may therefore be more representative of the true response but the description of romazarit effect is dependent on assumptions that have to be made about the evolution of RI over time, the time course of the placebo response and the nature of the effect of romazarit. We believe that the assumptions we have made are reasonable in terms of a simple description of the behaviour that might occur.
The mechanism of action of romazarit is not well defined. Observations of the time course of its effect in the rat collagen arthritis model shows a delay of about a week before reaching a parallel dose related shift in the response curve [3] . The effective concentrations observed in this animal model proved to be valid predictors of the concentrations associated with a therapeutic effect in humans.
We do not feel confident in distinguishing between the mechanisms of effect of romazarit either on the slope or as an offset to the disease progress curve because of the short duration of the study. An effect on the slope appeared to be somewhat better than on offset.
We conclude that romazarit has significant effects on the Ritchie Index. The use of population PKPD models has challenged us to describe the important components of the observed response. By identifying and quantifying the influence of each of these we can not only draw conclusions about the effect of a potential medicine but also predict the time course of the treatment response over the period of the trial. Prediction of treatment responses over a period greater than 6 months is not feasible in the absence of a better understanding of the mechanism of action of romazarit. We have identified a clear hypothesis about the general nature of the effect, i.e. whether it is on the slope of the disease progress curve or an offset to it. This hypothesis could be tested by a longer study based upon the insights derived from the present analysis.
